Opioid maker changes tack as scrutiny mounts

February 14, 2018 by Jean-Louis Doublet
This undated handout photo from the US Drug Enforcement Administration(DEA) shows 20 mg pills of OxyContin—the drug produced by Purdue Pharma

Accused of profiting from a deadly opioid crisis ravaging middle class America, the maker of the world's best-selling pain medication, Purdue Pharma, said Tuesday it is changing tack in the face of increasing scrutiny.

The privately-held firm, which made the fortune of the Sackler family of philanthropists, confirmed that it has asked its salespeople not to encourage doctors to prescribe the anti-pain medications, including the popular OxyContin, which are often abused by addicts.

"We have restructured and significantly reduced our commercial operation & our sales representatives will no longer promote opioids to prescribers," Purdue Pharma said.

Oversubscription of pain medications has led to dependence by millions of Americans and an explosion of fatal overdoses, including those of pop icon Prince and rocker Tom Petty.

Purdue Pharma is among manufacturers named by New York City in a $500 million lawsuit filed in January to recoup costs that could help battle the escalating opioid crisis.

The deadly toll from overdoses in New York doubled between 2010 and 2016, when more than 1,000 people died from opioid excess. More New Yorkers died from opioid overdoses than from car accidents and homicides combined, the suit claims.

The lawsuit, like hundreds of others, accuses manufacturers of deceptive marketing and distributors of over-supplying prescription painkillers, burdening the city with increased health care, criminal justice and law enforcement costs.

In October, President Donald Trump described the opioid crisis as a national public health emergency.

An estimated 2.4 million Americans are addicted to opiates, the narcotics that include , as well as heroin.

The Arthur M. Sackler Gallery in Washington is one of many bearing the name of the family that founded opioid maker Purdue Pharma

Family dynasty

Brothers Mortimer and Raymond Sackler founded Purdue Pharma. Another brother, Arthur, had a sizable stake.

All three are dead but the family name—synonymous with generous donations to the art world—lives on at multiple museums in the United States, in London and in Paris at the Louvre.

Other Sackler family members still sit, quietly, on Purdue Pharma's board of directors.

In October, The New Yorker magazine said that OxyContin had generated $35 billion for Purdue Pharma since hitting the market in 1995, a large part of which went to the Sacklers.

But the family remains discrete about its links with Purdue Pharma. The group's website does not identify the family members who serve on the company's board.

'Morally abhorrent'

In January, American photographer Nan Goldin began a public campaign about the link between opioids and the wealthy philanthropists.

Golden, a former opioid addict, formed the group PAIN (Prescription Addiction Intervention Now) and launched the hashtag #ShameonSackler.

The aim is to push Purdue Pharma and the Sacklers to finance programs for treatment and prevention, to limit prescriptions for opioids and to publicize their dangers.

Photographer Nan Goldin, a former opioid addict pictured in 2009, wants museums to refuse funding from the Sackler family, whose members sit on the board of OxyContin maker Purdue Pharma

Goldin also called on museums and universities that benefited from the Sacklers' largesse to refuse future donations.

Paradoxically, her crusade received support from Elizabeth Sackler, a daughter of Arthur, who told American media that "the is a national crisis and Purdue Pharma's role in it is morally abhorrent to me."

She underlined that her father, who died in 1987, played no role in the development and commercialization of OxyContin, and that his stake in Purdue Pharma was sold to his brothers before the drug was put on the market.

"None of his descendants have ever owned a share of Purdue stock nor benefited in any way from it or the sale of OxyContin," she said.

Arthur Sackler's widow Jillian also sought to put distance between her husband and the controversial drug.

"None of the charitable donations made by Arthur prior to his death, nor that I made on his behalf after his death, were funded by the production, distribution or sale of OxyContin or other revenue from Purdue Pharma. Period," she said in a statement to AFP.

"Passing judgment on Arthur's life's work through the lens of the opioid crisis some 30 years after his death is a gross injustice."

'Part of the solution'

Purdue Pharma posted on its website a warning about the effects of opioids and said it is committed "to being part of the solution by partnering with local law enforcement, state and local government agencies, and community groups across the country."

But, according to a report made public Monday by Democratic Senator Claire McCaskill, Purdue Pharma financially supported the Washington Legal Foundation, a group that in 2016 criticized recommendations of the Centers for Disease Control and Prevention aimed at limiting the prescription of opioids for cases of chronic pain.

The report lists a long series of medical associations specialized in the treatment of pain that Purdue Pharma and other opioid producers have helped financially.

"Organizations receiving substantial funding from manufacturers have, in fact, amplified and reinforced messages favoring increased use," McCaskill said.

Explore further: New York hits big pharma with $500mn lawsuit in opioid crisis

Related Stories

New York hits big pharma with $500mn lawsuit in opioid crisis

January 23, 2018
New York turned the screws on pharmaceutical giants in America's opioid epidemic, suing manufacturers for $500 million on Tuesday as a photographer kickstarted a petition to hold Purdue Pharma accountable as a recovering ...

Alabama files lawsuit against opioid manufacturer

February 6, 2018
Alabama on Tuesday filed a lawsuit against the manufacturer of OxyContin and other opioids, becoming the latest state seeking to hold drug companies accountable for an addiction epidemic.

OxyContin maker will stop promoting opioids to doctors

February 10, 2018
The maker of the powerful painkiller OxyContin said it will stop marketing opioid drugs to doctors, a surprise reversal following lawsuits that blamed the company for helping trigger the current drug abuse epidemic.

South Carolina sues drug manufacturer over opioid crisis

August 15, 2017
South Carolina has become the latest state to accuse a drug manufacturer of exacerbating its opioid drug crisis by using deceptive marketing, with the state's top prosecutor suing the maker of OxyContin.

Opioid makers gave $10M to advocacy groups amid epidemic

February 13, 2018
Companies selling some of the most lucrative prescription painkillers funneled millions of dollars to advocacy groups that in turn promoted the medications' use, according to a report released Monday by a U.S. senator.

Ohio sues five drugmakers over role in opioid crisis

May 31, 2017
The US state of Ohio on Wednesday sued five major producers of prescription opioid medications, accusing them of lying about the deadly risks the painkillers—at the center of a nationwide addiction crisis—posed to public ...

Recommended for you

Novel botulinum toxin compound relieves chronic pain

July 18, 2018
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to research by UCL, ...

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.